Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures "The European approval of Prolia is a ...

Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia® (denosumab) as a treatment to increase bone mass in men with osteoporosis at high ...

PROLIA (denosumab) 60mg subcutaneous injection by Amgen Amgen announced results from a 7-year, single-arm, open-label extension of the 3-year randomized, double-blind, placebo-controlled, multi-center ...

Please provide your email address to receive an email when new articles are posted on . The FDA today approved denosumab, an injectable treatment for postmenopausal women with osteoporosis who are at ...

Please provide your email address to receive an email when new articles are posted on . Cancer treatment-induced bone loss and skeletal-related events resulting from bone metastases cause significant ...

Bone is One of the Most Common Sites for Distant Metastases Affecting up to 75 percent of Patients with Advanced Breast Cancer THOUSAND OAKS, Calif., Nov. 8, 2010 ...

Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate ...

Severe hypocalcemia was found to be more common among patients with advanced chronic kidney disease with mineral and bone disorder who are taking Prolia for osteoporosis. The FDA has revised the ...

November 10, 2010 — In advanced breast cancer patients who have bone metastases, the novel biologic denosumab was superior to zoledronic acid in preventing skeletal-related events (SREs) and renal ...

Daiichi Sankyo Company, Limited announced that it has applied for additional indication of denosumab (product name: Pralia subcutaneous injection 60mg syringe) for rheumatoid arthritis-related ...

Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass. Health Canada approval based on robust Phase I and Phase III ...